SENSEI news

Sensei Biotherapeutics, Inc. has amended its Certificate of Incorporation to change its corporate name to Faeth Therapeutics, Inc., effective upon Delaware filing. The name change represents a rebranding of the biopharmaceutical company's corporate identity.

Sensei Biotherapeutics increased authorized Common Stock from an undisclosed prior amount to 300 million shares and authorized Preferred Stock at 10 million shares, totaling 310 million authorized shares. The amendment provides capital structure flexibility for potential financing, acquisitions, or …

Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17, 2026, issuing 10.5M Series B Preferred shares to Faeth shareholders and simultaneously raising $200M from investors. The transaction significantly expands the company's pipeline and provides substantial capital fo…